All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Keeping you up to date on recent developments in neurology, including: AI reveals drugs that may be repurposed for Alzheimer’s disease; Treating Parkinson’s disease symptoms with brain cell grafts; Astrocytes are more inflammatory in bipolar disease; Pain on the brain.
Keeping you up to date on recent developments in diagnostics, including: Rapid POC test for respiratory infections may reduce antibiotic use; Risk-stratification tools help conserve ventilator, ICU bed use; Diverse populations, long reads give genome insights; Neurons contribute to their own lack of regeneration.
At the 2021 Advances in Genome Biology and Technology meeting, John Greally had some unusual advice with respect to confounders in epigenomic studies. Epigenomics, he told the audience in his talk on "Thinking beyond the creode: epigenomics and human disease," has real promise for understanding genomic mechanisms of disease. "But possibly not in the way we think."
"Nothing is undruggable!" was the bold claim at the European Society of Medical Oncology Targeted Anticancer Therapies Virtual Congress 2021 the (ESMO-TAT).
In the public mind, fat and unhealthy are more or less synonymous. But reality is more complicated, as reality often is. Even among individuals with a BMI of 30 or higher, somewhere between 15% and 45% have metabolism typical of much lower-weight individuals.
Scientists, despite their best efforts, have not been able to identify a way to inhibit the oncoprotein Myc. Uropathogenic Escherichia coli, though, has apparently figured it out. In the Feb. 11, 2021, online issue of Nature Biotechnology, researchers reported that an UPEC-produced protease depleted cellular Myc and improved survival in mouse models of bladder and colon cancer.
Keeping you up to date on recent developments in oncology, including: Imaging studies offer clarity on impact of combo therapy in metastatic breast cancer; Antidiarrheal drug fights AML; Peering past gastrointestinal mucosa to find tumors; Nanosac to the rescue for solid tumor therapy.
A team led by researchers at Johns Hopkins University School of Medicine has developed bispecific antibodies that were able to target tumors driven by mutations in the tumor suppressor TP53 and the oncogene RAS, as well as subsets of T cells in T-cell malignancies.
